ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
Healthcare
$7.70 -0.75%
-$0.07 today
- Market cap
- $800.27M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
52W Low $7.23High $14.93
Volume 1.07M
Average 1.91M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$113.37M
FY 2025 · Annual
Investing Cash Flow
-$148.03M
FY 2025 · Annual
Financing Cash Flow
$247.66M
FY 2025 · Annual
+95.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.85M | 14.46M | 15.23M | 20.21M | 0 |
| Change in Working Capital | 4.07M | (445K) | 4.9M | 1.97M | (5.46M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.93M | (1.48M) | 0 | 1.83M | (7.25M) |
| Other Working Capital | 1.14M | 1.03M | 4.9M | 143K | 1.79M |
| Other Non-Cash Items | 1.35M | (1M) | (6.15M) | (8.1M) | 20.34M |
| Operating Cash Flow | (59.54M) | (75.14M) | (85.69M) | (112.66M) | (113.37M) |
| Capital Expenditures | (939K) | (2.08M) | (849K) | (1.19M) | (712K) |
| Acquisitions (Net) | 1.38M | 2.08M | 0 | 0 | 0 |
| Purchases of Investments | (69.63M) | (238.12M) | (239.24M) | (251.92M) | (399.82M) |
| Sales of Investments | 229M | 130.95M | 196.69M | 275.25M | 252.5M |
| Other Investing Activities | (1.38M) | (2.08M) | 0 | 0 | 0 |
| Investing Cash Flow | 158.44M | (109.25M) | (43.4M) | 22.14M | (148.03M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 50M | 25M | 85M | 125M | 247.66M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (866K) | 225K | 658K | 1.55M | 0 |
| Financing Cash Flow | 49.13M | 25.23M | 85.66M | 126.55M | 247.66M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 148.03M | (159.17M) | (43.43M) | 36.02M | (13.74M) |
| Free Cash Flow | (60.48M) | (77.22M) | (86.54M) | (113.85M) | (114.08M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$129.5M
+ D&A$1.2M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$5.5M
+ Other Non-Cash$20.3M
= Operating Cash Flow-$113.4M
- Capex-$712.0K
= Free Cash Flow-$114.1M
Analysis
FY2025 free cash flow is -$114.1M. FCF conversion is 88.1% of net income. Operating cash flow was -$113.4M, with capex of -$712.0K. The largest bridge item is Other Non-Cash at $20.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 23, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 |
Does ORIC generate free cash flow?
ORIC Pharmaceuticals, Inc. (ORIC) generated -$114.08M of free cash flow in fiscal 2025.
How much operating cash flow does ORIC produce?
Operating cash flow was -$113.37M, before capital expenditures of $712,000.00.
Continue the stock analysis
Jump to another research area for this company.